08
Apr

Portola Pharmaceuticals has snapped in the last piece to a Phase III program puzzle for its “breakthrough” anti-anticoagulant, painting a clear path to an accelerated regulatory submission later in the year.

…read more

Source: Portola says it’s ready to file ‘breakthrough’ anticoagulant antidote

    

0 No comments